Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · Real-Time Price · USD
676.69
-2.25 (-0.33%)
At close: Jul 17, 2026, 4:00 PM EDT
676.00
-0.69 (-0.10%)
After-hours: Jul 17, 2026, 6:14 PM EDT
Regeneron Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 28 analysts polled by S&P Global, Regeneron Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $820.72. The average 1-year stock price forecast is 21.28% higher than the current stock price, while the lowest is $641 (-5.27%) and the highest is $1,000 (+47.78%).
Price Target: $820.72 (+21.28%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Regeneron Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 17 | 18 | 18 | 16 | 16 | 16 |
| Buy | 2 | 4 | 4 | 5 | 5 | 5 |
| Hold | 8 | 7 | 7 | 8 | 8 | 8 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 27 | 29 | 29 | 29 | 29 | 29 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citi | Citi | Hold Maintains $700 | Hold | Maintains | $700 | +3.44% | Jul 16, 2026 |
| BMO Capital | BMO Capital | Buy Maintains $730 | Buy | Maintains | $730 | +7.88% | Jul 13, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Reiterates $860 → $856 | Buy | Reiterates | $860 → $856 | +26.50% | Jul 13, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $854 | Buy | Reiterates | $854 | +26.20% | Jul 9, 2026 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $788 → $730 | Hold | Maintains | $788 → $730 | +7.88% | Jul 8, 2026 |
Financial Forecast
Revenue This Year
15.87B
from 14.34B
Increased by 10.65%
Revenue Next Year
17.65B
from 15.87B
Increased by 11.21%
EPS This Year
45.99
from 44.31
Increased by 3.79%
EPS Next Year
54.76
from 45.99
Increased by 19.07%
EPS and Forward PE are based on non-GAAP adjusted numbers.